Ridolo Erminia, Incorvaia Cristoforo, Heffler Enrico, Cavaliere Carlo, Paoletti Giovanni, Canonica Giorgio Walter
Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, 43121 Parma, Italy.
IRCCS Humanitas Research Hospital, 20089 Milan, Italy.
J Pers Med. 2022 May 10;12(5):774. doi: 10.3390/jpm12050774.
Allergic diseases are particularly suitable for personalized medicine, because they meet the needs for therapeutic success, which include a known molecular mechanism of the disease, a diagnostic tool for that disease and a treatment that blocks this mechanism. A range of tools is available for personalized allergy diagnosis, including molecular diagnostics, treatable traits and omics (i.e., proteomics, epigenomics, metabolomics, transcriptomics and breathomics), to predict patient response to therapies, detect biomarkers and mediators and assess disease control status. Such tools enhance allergen immunotherapy. Higher diagnostic accuracy results in a significant increase (based on a greater performance achieved with personalized treatment) in efficacy, further increasing the known and unique characteristics of a treatment designed to work on allergy causes.
过敏性疾病特别适合个性化医疗，因为它们满足了治疗成功的需求，其中包括已知的疾病分子机制、针对该疾病的诊断工具以及阻断该机制的治疗方法。有一系列工具可用于个性化过敏诊断，包括分子诊断、可治疗特征和组学（即蛋白质组学、表观基因组学、代谢组学、转录组学和呼吸组学），以预测患者对治疗的反应、检测生物标志物和介质并评估疾病控制状态。这些工具可增强变应原免疫疗法。更高的诊断准确性会使疗效显著提高（基于个性化治疗取得的更好效果），进而进一步增加旨在针对过敏病因的治疗方法所具有的已知独特特性。
